Key Points
-
Venous thromboembolism (VTE) occurs as often as stroke, and recurs frequently, with around 30% of patients with VTE experiencing recurrence within 10 years
-
Occurrence of VTE, especially pulmonary embolism (PE), is associated with reduction in survival, and PE is an independent predictor of reduced survival for up to 3 months
-
VTE is associated with high health-care costs and increased disability-adjusted life-years
-
Despite identification of VTE risk factors, development of new prophylaxis regimens, and improved uptake of VTE prophylaxis, the occurrence of VTE is increasing
Abstract
Thrombosis can affect any venous circulation. Venous thromboembolism (VTE) includes deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism. VTE is a fairly common disease, particularly in older age, and is associated with reduced survival, substantial health-care costs, and a high rate of recurrence. VTE is a complex (multifactorial) disease, involving interactions between acquired or inherited predispositions to thrombosis and various risk factors. Major risk factors for incident VTE include hospitalization for surgery or acute illness, active cancer, neurological disease with leg paresis, nursing-home confinement, trauma or fracture, superficial vein thrombosis, and—in women—pregnancy and puerperium, oral contraception, and hormone therapy. Although independent risk factors for incident VTE and predictors of VTE recurrence have been identified, and effective primary and secondary prophylaxis is available, the occurrence of VTE seems to be fairly constant, or even increasing.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Souto, J. C. et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am. J. Hum. Genet. 67, 1452–1459 (2000).
Ariëns, R. A. et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 359, 667–671 (2002).
Larsen, T. B. et al. Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins. Epidemiology 14, 328–332 (2003).
Heit, J. A. et al. Familial segregation of venous thromboembolism. J. Thromb. Haemost. 2, 731–736 (2004).
Zöller, B., Ohlsson, H., Sundquist, J. & Sundquist, K. Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden. Thromb. Haemost. 109, 458–463 (2013).
Zöller, B., Li, X., Sundquist, J. & Sundquist, K. A nationwide family study of pulmonary embolism: identification of high risk families with increased risk of hospitalized and fatal pulmonary embolism. Thromb. Res. 130, 178–182 (2012).
Zöller, B., Li, X., Sundquist, J. & Sundquist, K. Shared familial aggregation of susceptibility to different manifestations of venous thromboembolism: a nationwide family study in Sweden. Br. J. Haematol. 157, 146–148 (2012).
Anderson, F. A. Jr et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. 151, 933–938 (1991).
Hansson, P. O., Welin, L., Tibblin, G. & Eriksson, H. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch. Intern. Med. 157, 1665–1670 (1997).
Silverstein, M. D. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch. Intern. Med. 158, 585–593 (1998).
Oger, E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb. Haemost. 83, 657–660 (2000).
Cushman, M. et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am. J. Med. 117, 19–25 (2004).
Heit, J. A. Venous thromboembolism: disease burden, outcomes and risk factors. J. Thromb. Haemost. 3, 1611–1617 (2005).
Spencer, F. A. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J. Gen. Intern. Med. 21, 722–727 (2006).
Naess, I. A. et al. Incidence and mortality of venous thrombosis: a population-based study. J. Thromb. Haemost. 5, 692–699 (2007).
Spencer, F. A. et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J. Thromb. Thrombolysis 28, 401–409 (2009).
Tagalakis, V., Patenaude, V., Kahn, S. R. & Suissa, S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am. J. Med. 126, 832.e13–832.e21 (2013).
Huang, W., Goldberg, R. J., Anderson, F. A., Kiefe, C. I. & Spencer, F. A. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985–2009). Am. J. Med. 127, 829–839.e5 (2014).
Rothwell, P. M. et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363, 1925–1933 (2004).
Koton, S. et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 312, 259–268 (2014).
White, R. H., Zhou, H. & Romano, P. S. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann. Intern. Med. 128, 737–740 (1998).
Schneider, D., Lilienfeld, D. E. & Im, W. The epidemiology of pulmonary embolism: racial contrasts in incidence and in-hospital case fatality. J. Natl Med. Assoc. 98, 1967–1972 (2006).
Zakai, N. A. et al. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation 129, 1502–1509 (2014).
Cheuk, B. L., Cheung, G. C. & Cheng, S. W. Epidemiology of venous thromboembolism in a Chinese population. Br. J. Surg. 91, 424–428 (2004).
Klatsky, A. L., Armstrong, M. A. & Poggi, J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am. J. Cardiol. 85, 1334–1337 (2000).
White, R. H., Zhou, H., Murin, S. & Harvey, D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb. Haemost. 93, 298–305 (2005).
Hooper, W. C., Holman, R. C., Heit, J. A. & Cobb, N. Venous thromboembolism hospitalizations among American Indians and Alaska Natives. Thromb. Res. 108, 273–278 (2002).
Heit, J. A. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch. Intern. Med. 162, 1245–1248 (2002).
Heit, J. A., Sobell, J. L., Li, H. & Sommer, S. S. The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. J. Thromb. Haemost. 3, 305–311 (2005).
Prandoni, P. et al. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125, 1–7 (1996).
Heit, J. A. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch. Intern. Med. 160, 761–768 (2000).
Hansson, P. O., Sörbo, J. & Eriksson, H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch. Intern. Med. 160, 769–774 (2000).
van Dongen, C. J., Vink, R., Hutten, B. A., Büller, H. R. & Prins, M. H. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch. Intern. Med. 163, 1285–1293 (2003).
Schulman, S. et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J. Thromb. Haemost. 4, 734–742 (2006).
Prandoni, P. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92, 199–205 (2007).
Spencer, F. A. et al. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch. Intern. Med. 168, 425–430 (2008).
Nieto, J. A. et al. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb. Haemost. 100, 789–796 (2008).
White, R. H., Chan, W. S., Zhou, H. & Ginsberg, J. S. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb. Haemost. 100, 246–252 (2008).
Kyrle, P. A., Rosendaal, F. R. & Eichinger, S. Risk assessment for recurrent venous thrombosis. Lancet 376, 2032–2039 (2010).
Verso, M. et al. Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thromb. Res. 130, 369–373 (2012).
Schulman, S. et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N. Engl. J. Med. 336, 393–398 (1997).
Kearon, C. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340, 901–907 (1999).
Agnelli, G. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N. Engl. J. Med. 345, 165–169 (2001).
Schulman, S. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N. Engl. J. Med. 332, 1661–1665 (1995).
Agnelli, G. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann. Intern. Med. 139, 19–25 (2003).
Prandoni, P. et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann. Intern. Med. 137, 955–960 (2002).
Kyrle, P. A. & Eichinger, S. The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism. Wien. Klin. Wochenschr. 115, 471–474 (2003).
Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H. & Ginsberg, J. S. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch. Intern. Med. 160, 3431–3436 (2000).
Murin, S., Romano, P. S. & White, R. H. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb. Haemost. 88, 407–414 (2002).
Kyrle, P. A. et al. The risk of recurrent venous thromboembolism in men and women. N. Engl. J. Med. 350, 2558–2563 (2004).
Laczkovics, C. et al. Risk of recurrence after a first venous thromboembolic event in young women. Haematologica 92, 1201–1207 (2007).
Kim, T. M. et al. Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea. Thromb. Res. 123, 436–443 (2009).
Eichinger, S. et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch. Intern. Med. 168, 1678–1683 (2008).
Romualdi, E., Squizzato, A. & Ageno, W. Abdominal obesity and the risk of recurrent deep vein thrombosis. Thromb. Res. 119, 687–690 (2007).
Garcia-Fuster, M. J. et al. Long-term prospective study of recurrent venous thromboembolism in patients younger than 50 years. Pathophysiol. Haemost. Thromb. 34, 6–12 (2005).
Heit, J. A. et al. Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism. J. Thromb. Haemost. 9, 1133–1142 (2011).
Agnelli, G., Becattini, C. & Prandoni, P. Recurrent venous thromboembolism in men and women. N. Engl. J. Med. 351, 2015–2018 (2004).
Baglin, T., Luddington, R., Brown, K. & Baglin, C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362, 523–526 (2003).
Baglin, T., Luddington, R., Brown, K. & Baglin, C. High risk of recurrent venous thromboembolism in men. J. Thromb. Haemost. 2, 2152–2155 (2004).
McRae, S., Tran, H., Schulman, S., Ginsberg, J. & Kearon, C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 368, 371–378 (2006).
Lijfering, W. M. et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 114, 2031–2036 (2009).
Le Gal, G. et al. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb. Haemost. 104, 498–503 (2010).
Christiansen, S. C., Lijfering, W. M., Helmerhorst, F. M., Rosendaal, F. R. & Cannegieter, S. C. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J. Thromb. Haemost. 8, 2159–2168 (2010).
Douketis, J. et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 342, d813 (2011).
Hutten, B. A. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J. Clin. Oncol. 18, 3078–3083 (2000).
Pinede, L. et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103, 2453–2460 (2001).
Prandoni, P. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100, 3484–3488 (2002).
Louzada, M. L., Majeed, H., Dao, V. & Wells, P. S. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul. Fibrinolysis 22, 86–91 (2011).
Louzada, M. L. et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 126, 448–454 (2012).
Chee, C. E. et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 123, 3972–3978 (2014).
Iorio, A. et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch. Intern. Med. 170, 1710–1716 (2010).
Baglin, T. et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J. Thromb. Haemost. 8, 2436–2442 (2010).
Kovacs, M. J. et al. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. J. Thromb. Haemost. 8, 1926–1932 (2010).
Schulman, S., Svenungsson, E. & Granqvist, S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104, 332–338 (1998).
Garcia, D., Akl, E. A., Carr, R. & Kearon, C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 122, 817–824 (2013).
Jayakody Arachchillage, D. & Greaves, M. The chequered history of the antiphospholipid syndrome. Br. J. Haematol. 165, 609–617 (2014).
van den Belt, A. G. et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch. Intern. Med. 157, 2227–2232 (1997).
Vossen, C. Y. et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J. Thromb. Haemost. 3, 459–464 (2005).
Brouwer, J. L. et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb. Haemost. 101, 93–99 (2009).
den Heijer, M. et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 109, 139–144 (2007).
Verhovsek, M. et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann. Intern. Med. 149, 481–490 (2008).
Douketis, J. et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann. Intern. Med. 153, 523–531 (2010).
Cosmi, B. et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 115, 481–488 (2010).
Palareti, G. et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 124, 196–203 (2014).
Tan, M., Mos, I. C., Klok, F. A. & Huisman, M. V. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review. Br. J. Haematol. 153, 168–178 (2011).
Le Gal, G. et al. Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. J. Thromb. Haemost. 9, 1126–1132 (2011).
Ho, W. K., Hankey, G. J., Quinlan, D. J. & Eikelboom, J. W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch. Intern. Med. 166, 729–736 (2006).
Gándara, E. et al. Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb. Haemost. 110, 1172–1179 (2013).
Zhu, T., Martinez, I. & Emmerich, J. Venous thromboembolism: risk factors for recurrence. Arterioscler. Thromb. Vasc. Biol. 29, 298–310 (2009).
Cushman, M. et al. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J. Thromb. Haemost. 4, 2199–2203 (2006).
Biere-Rafi, S. et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur. Heart J. 34, 1800–1806 (2013).
White, R. H., Murin, S., Wun, T. & Danielsen, B. Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism. J. Thromb. Haemost. 8, 987–997 (2010).
Douketis, J. D., Crowther, M. A., Foster, G. A. & Ginsberg, J. S. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am. J. Med. 110, 515–519 (2001).
Eichinger, S. et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch. Intern. Med. 164, 92–96 (2004).
Jiménez, D. et al. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb. Haemost. 95, 562–566 (2006).
Boutitie, F. et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 342, d3036 (2011).
Galanaud, J. P. et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J. Thromb. Haemost. 12, 436–443 (2014).
den Exter, P. L. et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood 122, 1144–1149 (2013).
Rodger, M. A. et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179, 417–426 (2008).
Eichinger, S., Heinze, G., Jandeck, L. M. & Kyrle, P. A. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 121, 1630–1636 (2010).
Tosetto, A. et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J. Thromb. Haemost. 10, 1019–1025 (2012).
Kyrle, P. A. & Eichinger, S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb. Haemost. 108, 1061–1064 (2012).
Poli, D. & Palareti, G. Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr. Opin. Pulm. Med. 19, 407–412 (2013).
den Exter, P. L., Kooiman, J. & Huisman, M. V. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J. Thromb. Haemost. 11, 998–1000 (2013).
Heit, J. A. Estimating the incidence of symptomatic postoperative venous thromboembolism: the importance of perspective. JAMA 307, 306–307 (2012).
Cohen, A. T. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 98, 756–764 (2007).
Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations—United States, 2007–2009. MMWR Morb. Mortal. Wkly Rep. 61, 401–404 (2012).
Cohoon, K. P. et al. Costs of venous thromboembolism associated with hospitalization for medical illness. Am. J. Manag. Care 21, e255–e263 (2015).
Cohoon, K. P. et al. Direct medical costs attributable to venous thromboembolism among persons hospitalized for major surgery: a population-based longitudinal study. Surgery 157, 423–431 (2015).
ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J. Thromb. Haemost. 12, 1580–1590 (2014).
Heit, J. A. et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch. Intern. Med. 159, 445–453 (1999).
Goldhaber, S. Z., Visani, L. & De Rosa, M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353, 1386–1389 (1999).
Janata, K. et al. Mortality of patients with pulmonary embolism. Wien. Klin. Wochenschr. 114, 766–772 (2002).
Andresen, M. S. et al. Mortality and recurrence after treatment of VTE: long term follow-up of patients with good life-expectancy. Thromb. Res. 127, 540–546 (2011).
Søgaard, K. K., Schmidt, M., Pedersen, L., Horváth-Puhó, E. & Sørensen, H. T. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation 130, 829–836 (2014).
Agnelli, G. & Becattini, C. Acute pulmonary embolism. N. Engl. J. Med. 363, 266–274 (2010).
Konstantinides, S. et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 96, 882–888 (1997).
Horlander, K. T., Mannino, D. M. & Leeper, K. V. Pulmonary embolism mortality in the United States, 1979–1998: an analysis using multiple-cause mortality data. Arch. Intern. Med. 163, 1711–1717 (2003).
Tsai, J., Grosse, S. D., Grant, A. M., Hooper, W. C. & Atrash, H. K. Trends in in-hospital deaths among hospitalizations with pulmonary embolism. Arch. Intern. Med. 172, 960–961 (2012).
Barsoum, M. K. et al. Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb. Res. 126, 373–378 (2010).
Heit, J. A. et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 160, 809–815 (2000).
Cushman, M. et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 101, 1243–1248 (2003).
Smeeth, L. et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 367, 1075–1079 (2006).
Sweetland, S. et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 339, b4583 (2009).
Bezemer, I. D., van der Meer, F. J., Eikenboom, J. C., Rosendaal, F. R. & Doggen, C. J. The value of family history as a risk indicator for venous thrombosis. Arch. Intern. Med. 169, 610–615 (2009).
Roach, R. E., Lijfering, W. M., Flinterman, L. E., Rosendaal, F. R. & Cannegieter, S. C. Increased risk of CVD after VT is determined by common etiologic factors. Blood 121, 4948–4954 (2013).
Cannegieter, S. C. et al. Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood 125, 229–235 (2015).
Heit, J. A. et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin. Proc. 76, 1102–1110 (2001).
Noboa, S., Mottier, D., Oger, E. & EPI-GETBO Study Group. Estimation of a potentially preventable fraction of venous thromboembolism: a community-based prospective study. J. Thromb. Haemost. 4, 2720–2722 (2006).
Samama, M. M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch. Intern. Med. 160, 3415–3420 (2000).
Geerts, W. H. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 381S–453S (2008).
Sweetland, S. et al. Smoking, surgery, and venous thromboembolism risk in women: United Kingdom cohort study. Circulation 127, 1276–1282 (2013).
White, R. H., Zhou, H. & Romano, P. S. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb. Haemost. 90, 446–455 (2003).
Edmonds, M. J., Crichton, T. J., Runciman, W. B. & Pradhan, M. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J. Surg. 74, 1082–1097 (2004).
Goldhaber, S. Z., Tapson, V. F. & DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am. J. Cardiol. 93, 259–262 (2004).
Anderson, F. A. Jr, Hirsh, J., White, K., Fitzgerald, R. H. Jr & Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry. Chest 124 (Suppl. 6), 349S–356S (2003).
White, R. H., Gettner, S., Newman, J. M., Trauner, K. B. & Romano, P. S. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N. Engl. J. Med. 343, 1758–1764 (2000).
Parkin, L. et al. Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation 125, 1897–1904 (2012).
Mantilla, C. B., Horlocker, T. T., Schroeder, D. R., Berry, D. J. & Brown, D. L. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology 99, 552–560 (2003).
Zakai, N. A., Wright, J. & Cushman, M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J. Thromb. Haemost. 2, 2156–2161 (2004).
Chopard, P., Spirk, D. & Bounameaux, H. Identifying acutely ill medical patients requiring thromboprophylaxis. J. Thromb. Haemost. 4, 915–916 (2006).
Barbar, S. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J. Thromb. Haemost. 8, 2450–2457 (2010).
Rothberg, M. B., Lindenauer, P. K., Lahti, M., Pekow, P. S. & Selker, H. P. Risk factor model to predict venous thromboembolism in hospitalized medical patients. J. Hosp. Med. 6, 202–209 (2011).
Spyropoulos, A. C. et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140, 706–714 (2011).
Woller, S. C. et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am. J. Med. 124, 947–954.e2 (2011).
Zakai, N. A., Callas, P. W., Repp, A. B. & Cushman, M. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. J. Thromb. Haemost. 11, 634–641 (2013).
Samama, M. M., Combe, S., Conard, J. & Horellou, M. H. Risk assessment models for thromboprophylaxis of medical patients. Thromb. Res. 129, 127–132 (2012).
Rothberg, M. B. Venous thromboembolism prophylaxis for medical patients: who needs it? JAMA Intern. Med. 174, 1585–1586 (2014).
Chew, H. K., Wun, T., Harvey, D., Zhou, H. & White, R. H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166, 458–464 (2006).
Blom, J. W. et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J. Thromb. Haemost. 4, 529–535 (2006).
Kucuk, O., Kwaan, H. C., Gunnar, W. & Vazquez, R. M. Thromboembolic complications associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 55, 702–706 (1985).
Liebman, H. A., Wada, J. K., Patch, M. J. & McGehee, W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer 50, 451–456 (1982).
Zangari, M. et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98, 1614–1615 (2001).
Knight, R., DeLap, R. J. & Zeldis, J. B. Lenalidomide and venous thrombosis in multiple myeloma. N. Engl. J. Med. 354, 2079–2080 (2006).
Meier, C. R. & Jick, H. Tamoxifen and risk of idiopathic venous thromboembolism. Br. J. Clin. Pharmacol. 45, 608–612 (1998).
Baron, J. A., Gridley, G., Weiderpass, E., Nyrén, O. & Linet, M. Venous thromboembolism and cancer. Lancet 351, 1077–1080 (1998).
Piccioli, A. et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J. Thromb. Haemost. 2, 884–889 (2004).
Tafur, A. J. et al. The association of active cancer with venous thromboembolism location: a population-based study. Mayo Clin. Proc. 86, 25–30 (2011).
Carrier, M. et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann. Intern. Med. 149, 323–333 (2008).
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H. & Francis, C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111, 4902–4907 (2008).
Ay, C. et al. Prediction of venous thromboembolism in cancer patients. Blood 116, 5377–5382 (2010).
Merrer, J. et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 286, 700–707 (2001).
Decousus, H. et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann. Intern. Med. 152, 218–224 (2010).
Goldhaber, S. Z. et al. Risk factors for pulmonary embolism. The Framingham Study. Am. J. Med. 74, 1023–1028 (1983).
Cogo, A. et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch. Intern. Med. 154, 164–168 (1994).
Dalen, J. E. Economy class syndrome: too much flying or too much sitting? Arch. Intern. Med. 163, 2674–2676 (2003).
Kuipers, S. et al. The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med. 4, e290 (2007).
Chandra, D., Parisini, E. & Mozaffarian, D. Meta-analysis: travel and risk for venous thromboembolism. Ann. Intern. Med. 151, 180–190 (2009).
Watson, H. G. & Baglin, T. P. Guidelines on travel-related venous thrombosis. Br. J. Haematol. 152, 31–34 (2011).
Ray, J. G. et al. Use of statins and the subsequent development of deep vein thrombosis. Arch. Intern. Med. 161, 1405–1410 (2001).
Lacut, K. et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam. Clin. Pharmacol. 18, 477–482 (2004).
Glynn, R. J. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360, 1851–1861 (2009).
Doggen, C. J. et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 24, 1970–1975 (2004).
Prandoni, P. et al. An association between atherosclerosis and venous thrombosis. N. Engl. J. Med. 348, 1435–1441 (2003).
Marcucci, R. et al. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am. J. Med. 115, 601–605 (2003).
Tsai, A. W. et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch. Intern. Med. 162, 1182–1189 (2002).
Sørensen, H. T., Horvath-Puho, E., Pedersen, L., Baron, J. A. & Prandoni, P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370, 1773–1779 (2007).
Zöller, B., Li, X., Sundquist, J. & Sundquist, K. Venous thromboembolism does not share strong familial susceptibility with coronary heart disease: a nationwide family study in Sweden. Eur. Heart J. 32, 2800–2805 (2011).
Barsoum, M. K. et al. Are myocardial infarction and venous thromboembolism associated? Population-based case-control and cohort studies. Thromb. Res. 134, 593–598 (2014).
Folsom, A. R. & Chamberlain, A. Lipoprotein(a) and venous thromboembolism. Am. J. Med. 121, e17 (2008).
Chamberlain, A. M., Folsom, A. R., Heckbert, S. R., Rosamond, W. D. & Cushman, M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 112, 2675–2680 (2008).
Chasan-Taber, L. & Stampfer, M. J. Epidemiology of oral contraceptives and cardiovascular disease. Ann. Intern. Med. 128, 467–477 (1998).
Rosendaal, F. R. Risk factors for venous thrombotic disease. Thromb. Haemost. 82, 610–619 (1999).
Gomes, M. P. & Deitcher, S. R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch. Intern. Med. 164, 1965–1976 (2004).
Grady, D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann. Intern. Med. 132, 689–696 (2000).
Grady, D., Hulley, S. B. & Furberg, C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 278, 477 (1997).
Heit, J. A. et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann. Intern. Med. 143, 697–706 (2005).
Adomaityte, J., Farooq, M. & Qayyum, R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb. Haemost. 99, 338–342 (2008).
van Hylckama Vlieg, A., Helmerhorst, F. M. & Rosendaal, F. R. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler. Thromb. Vasc. Biol. 30, 2297–2300 (2010).
Smith, N. L. et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292, 1581–1587 (2004).
James, A. H. Venous thromboembolism in pregnancy. Arterioscler. Thromb. Vasc. Biol. 29, 326–331 (2009).
Danilenko-Dixon, D. R. et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am. J. Obstet. Gynecol. 184, 104–110 (2001).
Roach, R. E. et al. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood 122, 4264–4269 (2013).
Sultan, A. A. et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood 121, 3953–3961 (2013).
Ludvigsson, J. F., Welander, A., Lassila, R., Ekbom, A. & Montgomery, S. M. Risk of thromboembolism in 14,000 individuals with coeliac disease. Br. J. Haematol. 139, 121–127 (2007).
Shantsila, E., Lip, G. Y. & Chong, B. H. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 135, 1651–1664 (2009).
Tsai, A. W. et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am. J. Hematol. 72, 192–200 (2003).
den Heijer, M., Lewington, S. & Clarke, R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J. Thromb. Haemost. 3, 292–299 (2005).
van Zaane, B. et al. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood 115, 4344–4349 (2010).
Severinsen, M. T. et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br. J. Haematol. 152, 360–362 (2011).
Boyle, S., White, R. H., Brunson, A. & Wun, T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 121, 4782–4790 (2013).
Grainge, M. J., West, J. & Card, T. R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375, 657–663 (2010).
Dentali, F. et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113, 5617–5623 (2009).
Barbui, T. et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115, 778–782 (2010).
Folsom, A. R. et al. Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol. Dial. Transplant. 25, 3296–3301 (2010).
Kayali, F., Najjar, R., Aswad, F., Matta, F. & Stein, P. D. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am. J. Med. 121, 226–230 (2008).
Brodsky, R. A. Paroxysmal nocturnal hemoglobinuria: stem cells and clonality. Hematology Am. Soc. Hematol. Educ. Program 2008, 111–115 (2008).
Bacani, A. K., Gabriel, S. E., Crowson, C. S., Heit, J. A. & Matteson, E. L. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum. 64, 53–61 (2012).
Holmqvist, M. E. et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 308, 1350–1356 (2012).
Arnulf, I. et al. Obstructive sleep apnea and venous thromboembolism. JAMA 287, 2655–2656 (2002).
Peng, Y. H. et al. Association between obstructive sleep apnea and deep vein thrombosis / pulmonary embolism: a population-based retrospective cohort study. Thromb. Res. 134, 340–345 (2014).
Austin, H. et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 110, 908–912 (2007).
Merkel, P. A. et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann. Intern. Med. 142, 620–626 (2005).
Sanson, B. J. et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 94, 3702–3706 (1999).
Folsom, A. R., Cushman, M., Tsai, M. Y., Heckbert, S. R. & Aleksic, N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am. J. Hematol. 71, 285–290 (2002).
Vossen, C. Y. & Rosendaal, F. R. The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level. J. Thromb. Haemost. 3, 1102–1103 (2005).
Vossen, C. Y. et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler. Thromb. Vasc. Biol. 25, 1992–1997 (2005).
Bombeli, T., Piccapietra, B., Boersma, J., Fehr, J. Decreased anticoagulant response to tissue factor pathway inhibitor in patients with venous thromboembolism and otherwise no evidence of hereditary or acquired thrombophilia. Thromb. Haemost. 91, 80–86 (2004).
Broze, G. J. Jr & Miletich, J. P. Human Protein Z. J. Clin. Invest. 73, 933–938 (1984).
Yin, Z. F. et al. Prothrombotic phenotype of protein Z deficiency. Proc. Natl Acad. Sci. USA 97, 6734–6738 (2000).
Han, X., Fiehler, R. & Broze, G. J. Jr. Isolation of a protein Z-dependent plasma protease inhibitor. Proc. Natl Acad. Sci. USA 95, 9250–9255 (1998).
Han, X., Huang, Z. F., Fiehler, R. & Broze, G. J. Jr. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 38, 11073–11078 (1999).
Souri, M., Koseki-Kuno, S., Iwata, H., Kemkes-Matthes, B. & Ichinose, A. A naturally occurring E30Q mutation in the Gla domain of protein Z causes its impaired secretion and subsequent deficiency. Blood 105, 3149–3154 (2005).
Uitte de Willige, S. et al. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 106, 4176–4183 (2005).
Press, R. D., Bauer, K. A., Kujovich, J. L. & Heit, J. A. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch. Pathol. Lab. Med. 126, 1304–1318 (2002).
Folsom, A. R. et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 99, 2720–2725 (2002).
Juul, K., Tybjaerg-Hansen, A., Schnohr, P. & Nordestgaard, B. G. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann. Intern. Med. 140, 330–337 (2004).
Chandler, W. L., Rodgers, G. M., Sprouse, J. T. & Thompson, A. R. Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch. Pathol. Lab. Med. 126, 1405–1414 (2002).
van Hylckama Vlieg, A. & Rosendaal, F. R. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J. Thromb. Haemost. 1, 2677–2678 (2003).
Wells, P. S., Langlois, N. J., Webster, M. A., Jaffey, J. & Anderson, J. A. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada—is it necessary to define a new upper reference range for factor VIII? Thromb. Haemost. 93, 842–846 (2005).
McGlennen, R. C. & Key, N. S. Clinical and laboratory management of the prothrombin G20210A mutation. Arch. Pathol. Lab. Med. 126, 1319–1325 (2002).
Koster, T., Blann, A. D., Briët, E., Vandenbroucke, J. P. & Rosendaal, F. R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152–155 (1995).
MacCallum, P. K. et al. Clotting factor VIII and risk of deep-vein thrombosis. Lancet 345, 804 (1995).
Kraaijenhagen, R. A. et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb. Haemost. 83, 5–9 (2000).
Bank, I. et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J. Thromb. Haemost. 3, 79–84 (2005).
van Hylckama Vlieg, A., van der Linden, I. K., Bertina, R. M. & Rosendaal, F. R. High levels of factor IX increase the risk of venous thrombosis. Blood 95, 3678–3682 (2000).
Meijers, J. C., Tekelenburg, W. L., Bouma, B. N., Bertina, R. M. & Rosendaal, F. R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N. Engl. J. Med. 342, 696–701 (2000).
Ohira, T. et al. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J. Thromb. Haemost. 5, 1455–1461 (2007).
Cushman, M., O'Meara, E. S., Folsom, A. R. & Heckbert, S. R. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 114, 2878–2883 (2009).
Smith, N. L. et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 121, 1382–1392 (2010).
Trégouët, D. A. et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 113, 5298–5303 (2009).
de Haan, H. G. et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 120, 656–663 (2012).
Cohen, W. et al. ABO blood group and von Willebrand factor levels partially explained the incomplete penetrance of congenital thrombophilia. Arterioscler. Thromb. Vasc. Biol. 32, 2021–2028 (2012).
Heit, J. A. et al. A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J. Thromb. Haemost. 10, 1521–1531 (2012).
Tang, W. et al. A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Genet. Epidemiol. 37, 512–521 (2013).
Tripodi, A., Chantarangkul, V., Martinelli, I., Bucciarelli, P. & Mannucci, P. M. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 104, 3631–3634 (2004).
Folsom, A. R., Cushman, M., Heckbert, S. R., Rosamond, W. D. & Aleksic, N. Prospective study of fibrinolytic markers and venous thromboembolism. J. Clin. Epidemiol. 56, 598–603 (2003).
Lisman, T., de Groot, P. G., Meijers, J. C. & Rosendaal, F. R. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105, 1102–1105 (2005).
André, P., Hartwell, D., Hrachovinová, I., Saffaripour, S. & Wagner, D. D. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc. Natl Acad. Sci. USA 97, 13835–13840 (2000).
Reitsma, P. H. & Rosendaal, F. R. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J. Thromb. Haemost. 2, 619–622 (2004).
Souto, J. C. et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 101, 1546–1551 (2000).
de Lange, M., Snieder, H., Ariëns, R. A., Spector, T. D. & Grant, P. J. The genetics of haemostasis: a twin study. Lancet 357, 101–105 (2001).
Vossen, C. Y. et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J. Thromb. Haemost. 2, 242–247 (2004).
Morange, P. E. et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br. J. Haematol. 128, 91–99 (2005).
Morange, P. E. & Trégouët, D. A. Current knowledge on the genetics of incident venous thrombosis. J. Thromb. Haemost. 11 (Suppl. 1), 111–121 (2013).
Oren, E., Smith, N. L., Doggen, C. J., Heckbert, S. R. & Lemaitre, R. N. Body mass index and the risk of venous thrombosis among postmenopausal women. J. Thromb. Haemost. 4, 2273–2275 (2006).
Severinsen, M. T. et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br. J. Haematol. 149, 273–279 (2010).
Vandenbroucke, J. P. et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344, 1453–1457 (1994).
Wu, O. et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb. Haemost. 94, 17–25 (2005).
Pomp, E. R., le Cessie, S., Rosendaal, F. R. & Doggen, C. J. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br. J. Haematol. 139, 289–296 (2007).
van Hylckama Vlieg, A. & Rosendaal, F. R. Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis. J. Thromb. Haemost. 1, 2186–2190 (2003).
van Vlijmen, E. F. et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 118, 2055–2061 (2011).
Martinelli, I. et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb. Haemost. 87, 791–795 (2002).
Herrington, D. M. et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler. Thromb. Vasc. Biol. 22, 1012–1017 (2002).
Rosendaal, F. R. et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br. J. Haematol. 116, 851–854 (2002).
Cushman, M. et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 292, 1573–1580 (2004).
van Stralen, K. J., Rosendaal, F. R. & Doggen, C. J. Minor injuries as a risk factor for venous thrombosis. Arch. Intern. Med. 168, 21–26 (2008).
Lindahl, T. L., Lundahl, T. H., Nilsson, L. & Andersson, C. A. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee—a prospective study. Thromb. Haemost. 81, 18–21 (1999).
Salvati, E. A. et al. The John Charnley Award: heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. Clin. Orthop. Relat. Res. 441, 40–55 (2005).
Blom, J. W., Doggen, C. J., Osanto, S. & Rosendaal, F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293, 715–722 (2005).
Libourel, E. J. et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor andlipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 87, 1068–1073 (2002).
Acknowledgements
The author was supported by grants from the National Heart, Lung, and Blood Institute under Award Number R01HL66216. Research support was also provided by the Mayo Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Heit, J. Epidemiology of venous thromboembolism. Nat Rev Cardiol 12, 464–474 (2015). https://doi.org/10.1038/nrcardio.2015.83
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2015.83
This article is cited by
-
Incidence and risk factors of perioperative deep vein thrombosis in patients undergoing primary hip arthroplasty via the direct anterior approach
Journal of Orthopaedic Surgery and Research (2024)
-
Multimorbidity disease clusters are associated with venous thromboembolism: an extended cross-sectional national study
Journal of Thrombosis and Thrombolysis (2024)
-
Trends in mortality related to venous thromboembolism in the European Union, 2012–2020
Internal and Emergency Medicine (2024)
-
Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling
Annals of Biomedical Engineering (2024)
-
A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State
Dermatology and Therapy (2024)